205 related articles for article (PubMed ID: 9674734)
41. Novel interactions between UFH and TFPI in children.
Newall F; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P; Ignjatovic V
Br J Haematol; 2010 Nov; 151(4):376-80. PubMed ID: 20880110
[TBL] [Abstract][Full Text] [Related]
42. In vitro effects of heparin and tissue factor pathway inhibitor on factor VII assays. possible implications for measurements in vivo after heparin therapy.
Bladbjerg EM; Larsen LF; Ostergaard P; Jespersen J
Blood Coagul Fibrinolysis; 2000 Dec; 11(8):739-45. PubMed ID: 11132652
[TBL] [Abstract][Full Text] [Related]
43. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients.
Demirkan F; Akarsu M; Sifil A; Tutucu KN
Nephron; 2002 May; 91(1):162-3. PubMed ID: 12021535
[TBL] [Abstract][Full Text] [Related]
44. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits.
Zitoun D; Bara L; Bloch MF; Samama MM
Thromb Res; 1994 Sep; 75(5):577-80. PubMed ID: 7992258
[TBL] [Abstract][Full Text] [Related]
45. Heparin induces mobilization of osteoprotegerin into the circulation.
Vik A; Brodin E; Sveinbjørnsson B; Hansen JB
Thromb Haemost; 2007 Jul; 98(1):148-54. PubMed ID: 17598007
[TBL] [Abstract][Full Text] [Related]
46. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
47. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin.
Kijowski R; Hoppensteadt D; Walenga J; Borris L; Lassen MR; Fareed J
Thromb Res; 1994 Apr; 74(1):53-64. PubMed ID: 8029808
[TBL] [Abstract][Full Text] [Related]
48. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
Hoppensteadt DA; Jeske W; Fareed J; Nicolaides AN
Int Angiol; 1996 Mar; 15(1):39-46. PubMed ID: 8739535
[TBL] [Abstract][Full Text] [Related]
49. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
[TBL] [Abstract][Full Text] [Related]
50. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
51. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
Vignoli A; Marchetti M; Balducci D; Barbui T; Falanga A
Haematologica; 2006 Feb; 91(2):207-14. PubMed ID: 16461305
[TBL] [Abstract][Full Text] [Related]
52. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits.
Warn-Cramer BJ; Maki SL; Rapaport SI
Thromb Haemost; 1993 Mar; 69(3):221-6. PubMed ID: 8470044
[TBL] [Abstract][Full Text] [Related]
53. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
54. Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography.
Chung J; Stevic I; Gantioqui J; Atkinson H; Chan AKC; Chan HHW
Blood Coagul Fibrinolysis; 2021 Jul; 32(5):305-311. PubMed ID: 34231501
[TBL] [Abstract][Full Text] [Related]
55. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
56. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins.
Bendz B; Andersen TO; Sandset PM
Blood Coagul Fibrinolysis; 2000 Jun; 11(4):343-8. PubMed ID: 10847421
[TBL] [Abstract][Full Text] [Related]
57. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
58. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
59. Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis.
Darwish NHE; Godugu K; Mousa SA
Thromb Res; 2021 Apr; 200():109-114. PubMed ID: 33582600
[TBL] [Abstract][Full Text] [Related]
60. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
Jeske W; Lormeau JC; Callas D; Iqbal O; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):193-200. PubMed ID: 7660142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
